QFIN HOLDINGS, INC. (QFIN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ADMA Biologics, Inc. Investors of Upcoming Deadline

Bernstein Liebhard LLP reminded Qfin Holdings investors of a November 27, 2026 deadline related to a securities fraud class action lawsuit commenced against the company. The notice asks current or former QFIN shareholders whether they should join; it provides no allegations, damages, or market reaction details.

Analysis

This is a procedural legal headline, not evidence of a finding of fraud or a quantified company liability. The supplied notice gives no alleged misstatements, class period, claimed damages, or company response, so it does not support a fundamental earnings or valuation revision. The near-term risk is sentiment and episodic volatility in QFIN as investors assess the underlying complaint; the filing deadline itself is not a merits ruling or a cash outflow. Over the next 1–3 months, materiality depends on the complaint’s allegations, any amended filing, court rulings, and whether the company discloses a credible financial or governance impact. Over 6–18 months, litigation would matter more if it exposes control or disclosure weaknesses that impair investor confidence or raise financing and compliance costs. Contrarian read: the headline may be mistaken for confirmation of wrongdoing, while the actual incremental information here is limited. Conversely, dismissing it without reviewing the complaint risks missing an allegation tied to a material reporting issue. No defensible directional trade without those details.

Key Decisions for Investors

• Do not initiate a short solely on the notice or treat the November 27 deadline as a liability trigger. First obtain the complaint and verify the alleged statements, class period, requested damages, and procedural status.
• For existing QFIN exposure, monitor company filings and court developments; reassess if allegations concern core financial reporting, if the company revises prior disclosures, or if guidance or reported metrics weaken. A dismissal or narrow ruling would reduce the litigation-overhang thesis.
• Treat any sharp headline-driven selloff as a watch item rather than an automatic entry: compare the price move with changes in the underlying earnings outlook and the complaint’s actual scope before considering a position.
• No options or pair trade is warranted on this information alone. Revisit only if the complaint establishes a material, company-specific catalyst or if QFIN’s price reaction materially exceeds any change in fundamentals.